AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
